Forest Labs Settles BYSTOLIC Patent Lawsuit

Jan. 3, 2013

By Dan Radovsky

Forest Laboratories (NYSE: FRX  ) announced today it has agreed to settle the patent infringement lawsuit it had brought against Glenmark Generics. That litigation was in response to Glenmark's seeking approval to produce a generic version of Forest's hypertension drug, BYSTOLIC (generic name, nebivolol).

Read this comlpete story at The Motley Fool.